COVID-19 Guidance

Clinical Guidance for Pediatric Patients

The ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve. 

COVID-19 Clinical Guidance Summary for Pediatric Patients with Rheumatic Disease   - June 18, 2020

ACR Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1   Published - July 23, 2020

How to cite this article: Wahezi DW, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, et al. American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1. Arthritis Rheumatol doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41455. E-pub ahead of print.

The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop or reduce medications.


Clinical Guidance Summary for Pediatric Patients with MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19   Updated - July 22, 2020

ACR Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 1   Published - July 23, 2020

How to cite this article: Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 1. Arthritis Rheumatol doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41454. E-pub ahead of print.

The recommendations for MIS-C focus on general guidance, diagnostic evaluation, and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki Disease. For hyperinflammation in COVID-19, the recommendations also focus on general guidance, as well as immunomodulatory treatment. 


Clinical Guidance for Adult Patients with Rheumatic Diseases

The ACR has developed clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic. Populations considered include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.

COVID-19 Clinical Guidance Summary for Adult Patients with Rheumatic Diseases   Updated - July 13, 2020

ACR Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1  Published - June 5, 2020

How to cite this article: Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. Arthritis Rheumatol doi: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41301. E-pub ahead of print.

 

You can also access the clinical guidance information on your iOS or Android mobile device. Download the free ACR Guideline and Criteria App on the App Store or Google Play.

© 2020 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us